Loading the latest PSX data…
Loading the latest PSX data…
Liven Pharma LimitedShariah-compliant
+4.31 (+10.00%) today
Market closed, last update Nov 17, 2026 10:37 PMThe Liven Pharma share price was Rs 47.42 (+10.00%) at the last PSX update (Nov 17, 2026 10:37 PM). LIVEN is a pharmaceuticals stock with a market value of Rs 5.4bn.
Last session's range17 Nov 2026
43.50100% up the range47.42
52-week range
27.8255% up the range63.48
Price limits (circuit breakers)
38.80100% up the range47.42
LIVEN ranks better than 15% of the 311 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
+26.4% over 6M(KSE-100 +5.5%)
Daily bars from PSX's end-of-day market summary. Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen LIVEN chart with levelsDownload LIVEN price history (CSV)Compare LIVEN with GLAXO
From daily closes to 2026-11-17. A description of the trend, not a forecast.
Trend reading
Uptrend
Down4 up · 0 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 42.19 | 44.81 | 46.11 | 48.73 | 50.03 |
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 2 Nov 15:45 | 1st quarter to 30 Sept | None | Rs -7.4m | -0.07 | – |
| 5 Oct 15:20 | Full year to 30 Jun | None | Rs -31.1m | -0.28 | 19 Oct – 26 Oct |
| 30 Apr 10:11 | 9 months to 31 Mar | None | Rs -5.9m | -0.06 | – |
| Measure | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales growth | −16.9% | −48.1% | – | – |
| Profit growth | – | −1,500.1% | – | – |
| EPS growth | – | −783.7% | – | – |
| Net margin | -29.4% | -459.2% | 17.0% | – |
| Measure | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales growth | +62.0% | – | – | – |
| Profit growth | – | – | – | – |
| EPS growth | – | – | – | – |
| Net margin | -51.6% | -13.5% | 51.7% | -341.9% |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Sales | Rs 106m | Rs 127m | Rs 245m | – |
| Profit after tax | Rs -31m | Rs -584m | Rs 42m | Rs -12m |
| Earnings per share (Rs) | -0.28 | -7.11 | 1.04 | -1.02 |
| Line item | Q1 2027 | Q3 2026 | Q2 2026 | Q1 2026 |
|---|---|---|---|---|
| Sales | Rs 14m | Rs 29m | Rs 55m | Rs 9m |
| Profit after tax | Rs -7m | Rs -4m | Rs 28m | Rs -30m |
| Earnings per share (Rs) | -0.07 | -0.03 | -0.30 | -0.28 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Gross margin | 25.2% | 14.1% | 25.5% | – |
| Net margin | -29.4% | -459.2% | 17.0% | – |
| EPS growth | 96.1% | -781.0% | 202.4% | 13.6% |
| PEG | -1.51 | 0.01 | 0.04 | -1.06 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report.
| Measure | LIVEN | Sector median | Reading |
|---|---|---|---|
| P/E | – | 12.2 | – |
| Dividend yield | – | 5.1% | – |
| Net margin | -29.4% | 9.4% | Below peers |
| EPS growth | – | +29.7% | – |
| 1-year return | −2.3% | −14.9% | Above peers |
Estimate a fair value for LIVEN (Graham, Lynch, DCF)LIVEN pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your LIVEN dividend income after tax
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
15th of 18
Rs 5.4bn
1-year return
3rd of 15
-2.3%
Net margin
16th of 16
-29.4%
danioPSX score
13th of 13
15/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 106.1bn | −1.89% | 9.7 | 6.1% | −15.4% | 87 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.5bn | +0.18% | 10.6 | 4.4% | −7.6% | 81 |
| HALEONHaleon Pakistan Limited | Rs 79.8bn | −1.15% | 12.2 | 3.6% | −16.6% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.1bn | +0.89% | 12.4 | 5.4% | −14.3% | 78 |
| SEARLThe Searle Company Limited | Rs 46.6bn | −0.37% | 12.0 | – | −23.6% | 53 |
| AGPAGP Limited | Rs 43.2bn | −0.84% | 24.1 | 5.1% | −18.3% | 49 |
| HPLHoechst Pakistan Limited | Rs 38.8bn | +0.53% | 11.1 | 6.9% | −2.7% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.7bn | −0.96% | 22.8 | 1.6% | −9.0% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.4bn | −0.74% | 17.7 | – | −23.2% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | −0.60% | 18.2 | – | −10.8% | 45 |
| MACTERMacter International Limited | Rs 11.7bn | −1.08% | 3.7 | – | −27.9% | 52 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +0.79% | 11.6 | – | +39.6% | 65 |
| LIVENThis stock · Liven Pharma Limited | Rs 5.4bn | +10.00% | – | – | −2.3% | 15 |
Swipe the table sideways for more columns.
| Date | Who | Trade | Shares | Price | Value | Holding after | Notice |
|---|---|---|---|---|---|---|---|
| 27 Aug 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 11,847 | 43.03 | Rs 510k | 48,895,55243.33% | Notice |
| 27 Aug 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 69 | 43.03 | Rs 3k | 48,895,48343.33% | Notice |
| 27 Aug 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 2,500 | 37.26 | Rs 93k | 48,892,98343.33% | Notice |
| 15 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 5,000 | 40.85 | Rs 204k | 48,981,96943.33% | Notice |
| 15 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 10,000 | 41.00 | Rs 410k | 48,971,96943.33% | Notice |
| 15 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 10,000 | 41.01 | Rs 410k | 48,961,96943.33% | Notice |
| 16 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 10,000 | 40.75 | Rs 408k | 48,951,96943.33% | Notice |
| 17 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 41.05 | Rs 41k | 48,950,96943.33% | Notice |
| 17 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 2,700 | 41.15 | Rs 111k | 48,948,26943.33% | Notice |
| 18 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,495 | 40.30 | Rs 60k | 48,946,77443.33% | Notice |
| 24 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 89,375 | 40.99 | Rs 3.7m | 48,937,38943.33% | Notice |
| 6 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 20,000 | 40.70 | Rs 814k | 48,917,38943.33% | Notice |
| 6 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 10,000 | 40.31 | Rs 403k | 48,907,38943.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 5,000 | 42.71 | Rs 214k | 49,041,97043.34% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,040,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,038,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,038,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 5,000 | 42.71 | Rs 214k | 49,033,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,032,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,031,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,030,97043.33% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,028,97043.32% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 1,000 | 42.71 | Rs 43k | 49,028,97043.32% | Notice |
| 14 Jul 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 32,001 | 42.71 | Rs 1.4m | 48,996,96943.33% | Notice |
| 15 Jun 26 | Kaashif Hussain SiddiqueExecutive Director | SoldReady | 10,000 | 40.50 | Rs 405k | 48,986,96943.33% | Notice |
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.
Where the price sits in its 52-week range
Low 27.8246% of the way upHigh 70.68
Data: PSX Data Portal (Nov 17, 2026 10:37 PM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell LIVEN. Official PSX page for LIVEN